Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Camizestrant is well tolerated, with antitumor activity in combination with CDK4/6i. These results support the evaluation of camizestrant 75 mg plus standard CDK4/6i doses in phase III trials.
Authors
- Bairu Zhang (ORCID: https://orcid.org/0000-0002-2753-9407)
- Erika Hamilton (ORCID: https://orcid.org/0000-0002-1911-0336)
- Manish R. Patel (ORCID: https://orcid.org/0000-0001-6836-2364)
- Begoña Bermejo (ORCID: https://orcid.org/0000-0001-7773-5994)
- Iván Victoria (ORCID: https://orcid.org/0000-0002-8733-6089)
- Peter Kabos (ORCID: https://orcid.org/0000-0003-1500-471X)
- Chris Twelves (ORCID: https://orcid.org/0000-0002-1849-7153)
- Andy Sykes (ORCID: https://orcid.org/0000-0003-2257-4841)
- Alastair Mathewson
- Mafalda Oliveira (ORCID: https://orcid.org/0000-0001-9152-8799)
- Anne Caroline Armstrong (ORCID: https://orcid.org/0000-0002-0774-7006)
- Carmela Ciardullo (ORCID: https://orcid.org/0000-0002-0809-2136)
- Teresa Klinowska (ORCID: https://orcid.org/0000-0003-1997-7340)
- Nicholas C. Turner (ORCID: https://orcid.org/0000-0001-8937-0873)
- Christos Vaklavas (ORCID: https://orcid.org/0000-0002-9919-2748)
- Christopher J. Morrow (ORCID: https://orcid.org/0000-0003-1524-9426)
- Manuel Ruíz-Borrego (ORCID: https://orcid.org/0000-0002-1181-5622)
- Irene Moreno (ORCID: https://orcid.org/0000-0001-5027-6388)
- Justin P.O. Lindemann (ORCID: https://orcid.org/0000-0003-1531-9754)
- Jason Incorvati
- Eva Ciruelos (ORCID: https://orcid.org/0000-0002-2796-1042)
- Richard D. Baird (ORCID: https://orcid.org/0000-0001-7071-6483)
- Jincheng Yang (ORCID: https://orcid.org/0000-0002-4813-1056)
Institutions
- AstraZeneca (United Kingdom) (GB)
- Hebron University (PS)
- Fox Chase Cancer Center (US)
- University of Leeds (GB)
- Royal Marsden NHS Foundation Trust (GB)
- University of Colorado Boulder (US)
- Breast Cancer Research Foundation (US)
- University of Utah (US)
- Leeds Teaching Hospitals NHS Trust (GB)
- Breast Cancer Now (GB)
- Huntsman Cancer Institute (US)
- Cancer Research UK (GB)
- University of Colorado System (US)
- Research Institute Hospital 12 de Octubre (ES)
- Cancer Research UK Cambridge Center (GB)
- AstraZeneca (South Korea) (KR)
- Hospital Clínico Universitario de Valencia (ES)
- Centro Oncológico de Galicia (ES)
- Sarah Cannon (US)
- Hospital Universitario 12 De Octubre (ES)
- AstraZeneca (Australia) (AU)
- AstraZeneca (Netherlands) (NL)
- AstraZeneca (Singapore) (SG)
- Hospital Clínic de Barcelona (ES)
- AstraZeneca (Brazil) (BR)
- Sarasota Memorial Hospital (US)
- Vall d'Hebron Hospital Universitari (ES)
- The Christie Hospital (GB)
- The Christie NHS Foundation Trust (GB)
- Tennessee Oncology (US)
- Hospital Universitario HM Sanchinarro (ES)
- AstraZeneca (Spain) (ES)
- AstraZeneca (United States) (US)
- Hospital Universitario Virgen del Rocío (ES)
- University of Colorado Denver (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-08-11
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-1198
- Citations
- 2
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- AstraZeneca
- Cancer Research UK
- National Institute for Health and Care Research
- NIHR Cambridge Biomedical Research Centre